B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

MMP14

MOLECULAR TARGET

matrix metallopeptidase 14

UniProt: AAF24178NCBI Gene: 432317 compounds

MMP14 (matrix metallopeptidase 14) is targeted by 17 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting MMP14

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1epigalocatechin gallate5.40220
2clioquinol4.0355
3cgs 27023a3.7642
4marimastat3.4731
5ilomastat3.4029
6prinomastat2.9418
7chloroxine2.7114
8cts 10272.6413
9batimastat2.4811
10tiludronic acid2.087
11ro 3197901.795
12bdb n 5 adamantan 1 yl 6h 1 3 4 thiadiazin 2 yl 2 benzenesulfonylamino propionamide 1.102
13Resveratrol0.691
14Astemizole Antihistamine drug now withdrawn from0.691
15Leflunomide0.691
16Propafenone0.691
17Thioridazine0.691

About MMP14 as a Drug Target

MMP14 (matrix metallopeptidase 14) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 17 compounds with documented MMP14 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

MMP14 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.